BCMA-话题@MedSci

#BCMA#

29篇内容 | 1211人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1460228, encodeId=895714602285a, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=GSK治疗多发性骨髓瘤的抗BCMA药物获批，再度回归抗肿瘤领域, objectType=article, longId=199021, objectId=957e19902101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=957e19902101, replyNumber=0, likeNumber=49, createdTime=2020-08-10, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=957e19902101, moduleTitle=GSK治疗多发性骨髓瘤的抗BCMA药物获批，再度回归抗肿瘤领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=957e19902101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460227, encodeId=d98b146022eba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, objectType=article, longId=198901, objectId=876c19890119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876c19890119, replyNumber=0, likeNumber=40, createdTime=2020-08-08, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876c19890119, moduleTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=876c19890119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460226, encodeId=c5d414602263c, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者, objectType=article, longId=197577, objectId=fa9619e5777b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9619e5777b, replyNumber=0, likeNumber=37, createdTime=2020-07-17, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9619e5777b, moduleTitle=靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9619e5777b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460225, encodeId=b592146022510, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=Sci Rep：BCMA受体作为系统性红斑狼疮生物标志物的分析, objectType=article, longId=192496, objectId=6c2f1924968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c2f1924968d, replyNumber=0, likeNumber=38, createdTime=2020-04-20, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c2f1924968d, moduleTitle=Sci Rep：BCMA受体作为系统性红斑狼疮生物标志物的分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c2f1924968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460224, encodeId=00b51460224a4, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, objectType=article, longId=187393, objectId=e5f218e3936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5f218e3936c, replyNumber=0, likeNumber=35, createdTime=2020-02-05, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5f218e3936c, moduleTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5f218e3936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460223, encodeId=e2b31460223ad, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, objectType=article, longId=184903, objectId=60b518490392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60b518490392, replyNumber=0, likeNumber=36, createdTime=2019-12-19, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60b518490392, moduleTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60b518490392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460222, encodeId=030b146022212, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效, objectType=article, longId=180386, objectId=5179180386b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5179180386b8, replyNumber=0, likeNumber=46, createdTime=2019-10-03, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5179180386b8, moduleTitle=Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5179180386b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460221, encodeId=63941460221ba, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞, objectType=article, longId=179638, objectId=933c1e9638de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933c1e9638de, replyNumber=0, likeNumber=33, createdTime=2019-09-19, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933c1e9638de, moduleTitle=科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933c1e9638de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, objectType=article, longId=178211, objectId=25671e8211a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25671e8211a0, replyNumber=0, likeNumber=26, createdTime=2019-08-28, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25671e8211a0, moduleTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25671e8211a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460219, encodeId=e4d9146021948, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, objectType=article, longId=168735, objectId=7d54168e353a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d54168e353a, replyNumber=0, likeNumber=41, createdTime=2019-06-20, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d54168e353a, moduleTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d54168e353a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460218, encodeId=168514602184f, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=科济生物在2018ASH年会发布CAR-BCMA-T研究结果, objectType=article, longId=155134, objectId=d16515513478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16515513478, replyNumber=0, likeNumber=45, createdTime=2018-12-06, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16515513478, moduleTitle=科济生物在2018ASH年会发布CAR-BCMA-T研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16515513478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460217, encodeId=53c0146021ee4, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=Blood：APRIL，BCMA和TACI双抗原靶向的嵌合型抗原受体，在多发性骨髓瘤中的应用前景。, objectType=article, longId=125160, objectId=e657125160d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e657125160d8, replyNumber=0, likeNumber=26, createdTime=2018-01-01, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e657125160d8, moduleTitle=Blood：APRIL，BCMA和TACI双抗原靶向的嵌合型抗原受体，在多发性骨髓瘤中的应用前景。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e657125160d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460216, encodeId=9972146021612, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=2016MBCMA股前外侧皮瓣临床应用指南（征求意见稿）发布, objectType=article, longId=79689, objectId=8884e968978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8884e968978, replyNumber=0, likeNumber=0, createdTime=2016-10-11, rootId=0, userName=yykkxiaodou, userId=85f46265562, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8884e968978, moduleTitle=2016MBCMA股前外侧皮瓣临床应用指南（征求意见稿）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8884e968978)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BCMA

2020-05-29

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

GSK治疗多发性骨髓瘤的抗BCMA药物获批，再度回归抗肿瘤领域

2020-08-10

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤

2020-08-08

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者

2020-07-17

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

Sci Rep：BCMA受体作为系统性红斑狼疮生物标志物的分析

2020-04-20

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请

2020-02-05

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％

2019-12-19

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

Blood：γ分泌酶抑制剂可增强BCMA靶向CAR T细胞疗法的功效

2019-10-03

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞

2019-09-19

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点

2019-08-28

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA

2019-06-20

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

科济生物在2018ASH年会发布CAR-BCMA-T研究结果

2018-12-06

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

Blood：APRIL，BCMA和TACI双抗原靶向的嵌合型抗原受体，在多发性骨髓瘤中的应用前景。

2018-01-01

yykkxiaodou (审核中...)

前往app查看评论内容

#BCMA#

2016MBCMA股前外侧皮瓣临床应用指南（征求意见稿）发布

2016-10-11

科室
- - 订阅+
  - 更多科室
工具
服务